Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

izorlisib (MEN1611)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Menarini, Roche

Drug class:

PI3K inhibitor

Related drugs:

›

PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria trastuzumab + MEN1611 Sensitive : C2	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria trastuzumab + MEN1611 Sensitive : C2
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
PTEN deletion	HER2 Positive Breast Cancer	PTEN deletion	HER2 Positive Breast Cancer	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D
PIK3CA H1047R	Endometrial Cancer	PIK3CA H1047R	Endometrial Cancer	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D
PIK3CA H1047R	Colorectal Cancer	PIK3CA H1047R	Colorectal Cancer	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D
PIK3CA H1047R	Breast Cancer	PIK3CA H1047R	Breast Cancer	trastuzumab + MEN1611 Sensitive: D – Preclinical trastuzumab + MEN1611 Sensitive : D	trastuzumab + MEN1611 Sensitive: D – Preclinical trastuzumab + MEN1611 Sensitive : D
PIK3CA K111N	Breast Cancer	PIK3CA K111N	Breast Cancer	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D
PIK3CA H1047R	Ovarian Cancer	PIK3CA H1047R	Ovarian Cancer	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	trastuzumab + MEN1611 Sensitive: D – Preclinical trastuzumab + MEN1611 Sensitive : D	trastuzumab + MEN1611 Sensitive: D – Preclinical trastuzumab + MEN1611 Sensitive : D
PTEN deletion	Gastric Cancer	PTEN deletion	Gastric Cancer	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D	MEN1611 Sensitive: D – Preclinical MEN1611 Sensitive : D
PIK3CA wild-type+ ESR1 wild-type	Breast Cancer	PIK3CA wild-type+ ESR1 wild-type	Breast Cancer	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D
PIK3CA mutation + ESR1 wild-type	Breast Cancer	PIK3CA mutation + ESR1 wild-type	Breast Cancer	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D
PIK3CA mutation + ESR1 mutation	Breast Cancer	PIK3CA mutation + ESR1 mutation	Breast Cancer	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D	MEN1611 + elacestrant Sensitive: D – Preclinical MEN1611 + elacestrant Sensitive : D